HighTower Advisors’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$229K Buy
7,037
+941
+15% +$32.6K ﹤0.01% 3439
2026
Q2
$238K Buy
+6,096
New +$197K ﹤0.01% 3411
2026
Q1
– Sell
-7,533
Closed -$265K – 3954
2025
Q4
$265K Buy
+7,533
New +$267K ﹤0.01% 3150
2025
Q3
– Sell
-9,554
Closed -$253K – 4078
2025
Q2
$253K Buy
9,554
+73
+0.8% +$1.92K ﹤0.01% 3079
2025
Q1
$229K Buy
9,481
+4,020
+74% +$127K ﹤0.01% 3075
2024
Q4
$220K Sell
5,461
-2,521
-32% -$144K ﹤0.01% 3126
2024
Q3
$507K Buy
7,982
+3,247
+69% +$190K ﹤0.01% 2391
2024
Q2
$251K Sell
4,735
-383
-7% -$25.1K ﹤0.01% 2868
2024
Q1
$419K Buy
+5,118
New +$228K ﹤0.01% 2404
2021
Q4
– Sell
-11,561
Closed -$72K – 3492
2021
Q3
$72K Sell
11,561
-120
-1% -$741 ﹤0.01% 2895
2021
Q2
$71K Buy
11,681
+882
+8% +$5.24K ﹤0.01% 2856
2021
Q1
$68K Buy
+10,799
New +$76K ﹤0.01% 2798
2020
Q4
– Sell
-10,601
Closed -$62K – 2849
2020
Q3
$62K Sell
10,601
-929
-8% -$6.4K ﹤0.01% 2289
2020
Q2
$83K Buy
11,530
+1,804
+19% +$12K ﹤0.01% 2150
2020
Q1
$44K Buy
+9,726
New +$59.8K ﹤0.01% 2021
2019
Q2
– Sell
-21,848
Closed -$217K – 2520
2019
Q1
$217K Hold
21,848
– – ﹤0.01% 1908
2018
Q4
$167K Buy
21,848
+2,012
+10% +$24.1K ﹤0.01% 1884
2018
Q3
$344K Buy
+19,836
New +$236K ﹤0.01% 1658

Other funds holding VKTX

HighTower Advisors's VKTX Position: Q3 2026 in Review

HighTower Advisors increased its Viking Therapeutics (VKTX) stake by 15% in Q3 2026, buying an estimated $32.6K and bringing the position to 7,037 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #3439.

HighTower Advisors first reported a position in VKTX in Q3 2018 and has held it in 18 quarters since. The position peaked at $507K in Q3 2024. 357 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • HighTower Advisors held 7,037 shares of Viking Therapeutics worth $229K as of Q3 2026.
  • HighTower Advisors bought 941 Viking Therapeutics shares in Q3 2026, an estimated $32.6K.
  • Viking Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #3439 holding.
  • HighTower Advisors first reported a position in Viking Therapeutics in Q3 2018 and has held it in 18 quarters since.
  • HighTower Advisors's Viking Therapeutics position peaked at $507K in Q3 2024.
  • 357 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.